DeepQure
PrivateLast Round
Series C
Apr 28, 2025
Company Overview
DeepQure is a medical device company that develops extravascular renal denervation systems for the treatment of resistant hypertension and other cardiovascular conditions.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
DeepQure Comparables
Compare DeepQure with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ablative Solutions | 81% | |
| Otsuka Holdings | 80% | |
| Cortex, Inc. | 79% | |
DeepQure Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 28, 2025 |
DeepQure Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Sui Generis Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 3, 2025
Jason G. Jones appointed as Global Vice President of Clinical & Regulatory Affairs.
- Jun 1, 2025
Monthly visitors grew 118% MoM.
DeepQure Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about DeepQure's valuation, stock price, and market status.